Touchlight

Executive Summary

Touchlight is a UK-based biotechnology company that has developed a proprietary cell-free DNA synthesis platform, dbDNA™, enabling rapid, scalable, and high-purity production of synthetic DNA vectors. Unlike traditional bacterial fermentation methods, Touchlight's enzymatic process eliminates contaminants and reduces production timelines, making it well-suited for gene therapy, mRNA vaccines, and gene editing applications. The company provides manufacturing services from research to GMP grade, positioning itself as a key enabler for the growing demand for DNA-based therapeutics. With over 15 years of operation, Touchlight has established itself as a leader in alternative DNA manufacturing, attracting partnerships with major pharmaceutical and biotechnology firms. The platform's advantages in speed, purity, and scalability are critical as the industry moves toward personalized medicine and rapid pandemic response. Touchlight's business model as a CDMO and technology licensor offers recurring revenue streams and exposure to multiple therapeutic areas. The company's ongoing efforts to expand capacity and secure regulatory approvals are expected to drive near-term growth. Given its strategic position in the accelerating gene therapy and vaccine markets, Touchlight represents a compelling investment opportunity with significant upside potential.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major Partnership for mRNA Vaccine Manufacturing70% success
• Q4 2026GMP Certification of New Manufacturing Facility80% success
• Q2 2026Publication of Preclinical Data Demonstrating dbDNA Superiority in Gene Therapy85% success